



ASO Author Reflections: The Beneficial Effect of High-Volume Center Experience on Surgical Outcomes After Total Pancreatectomy

Thomas F. Stoop, BSc^{1,2,3}, and Marco Del Chiaro, MD, PhD^{1,3}

¹Pancreatic Surgery Unit, Division of Surgery, Department of Science Intervention and Technology (CLINTEC), Karolinska Institutet at Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden; ²Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; ³Division of Surgical Oncology, Department of Surgery, University of Colorado, Aurora, CO

PAST

The role of total pancreatectomy (TP) is historically highly debatable. TP has failed to show a more radical outcome in the treatment of pancreatic cancer in comparison with partial pancreatectomy.¹ Moreover, TP has been associated with severe metabolic sequelae and potentially life-threatening long-term complications;² however, for some indications, TP remains the only treatment option for some pancreatic diseases.³

PRESENT

In recent years, the number of TPs worldwide has increased, since its subsequent endocrine and exocrine insufficiency seems to be better manageable, with an acceptable impact on quality of life.⁴ Some ‘new’ pancreatic diseases (i.e. intraductal papillary mucinous neoplasms [IPMNs]) require a TP in some cases in order to achieve cure.⁵ At the same time, with the improvement in the systemic treatment of pancreatic cancer,⁶ TP can be used in cases of locally extended disease.

In the Karolinska University Hospital, the annual relative and absolute number of TPs has also increased,⁷ mainly as a consequence of a lower threshold for

performing TPs for IPMNs and adenocarcinomas, particularly through intraoperative decision making to carefully select only those patients in which TP will be of oncological benefit. Surgical outcomes improved significantly as surgical volumes increased to more than 20 TPs per year, especially after TP with concomitant resection of adjacent structures.

The current satisfying results of TP without extended resections justify its role as treatment for diffuse or multifocal premalignant pancreatic diseases. Besides the oncological benefit of TP as a treatment option for resectable pancreatic cancer with repetitive isolated neck margin, the value of extended TP for borderline resectable and locally advanced pancreatic cancer seems to be feasible and safe if performed in high-volume, experienced centers.

FUTURE

The present study implicates that TP should be preferably performed in high-volume, experienced centers, especially in cases of extended resections; however, larger series are required to precisely investigate the short- and long-term surgical and oncological outcomes after both standard and extended TP compared with partial pancreatectomies. These results also need to be carefully weighted with the long-term consequences in terms of quality of life and chronic complications.

DISCLOSURES Thomas F. Stoop and Marco Del Chiaro have no disclosures to declare.

© The Author(s) 2020

First Received: 23 July 2020

Accepted: 25 July 2020;

Published Online: 11 August 2020

T. F. Stoop, BSc

e-mail: t.f.stoop@amsterdamumc.nl

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

REFERENCES

1. Ihse I, Anderson H, Andren S. Total pancreatectomy for cancer of the pancreas: is it appropriate? *World J Surg* 1996;20(3):288–94.
2. Sarr MG, Behms KE, van Heerden JA. Total pancreatectomy. An objective analysis of its use in pancreatic cancer. *Hepatogastroenterology* 1993;40(5):418–21.
3. Del Chiaro M, Rangelova E, Segersvard R, Arnelo U. Are there still indications for total pancreatectomy? *Updates Surg* 2016;68(3):257–63.
4. Scholten L, Stoop TF, Del Chiaro M, et al. Systematic review of functional outcome and quality of life after total pancreatectomy. *Br J Surg* 2019;106(13):1735–46.
5. Scholten L, van Huijgevoort NCM, Bruno MJ, et al. Surgical management of intraductal papillary mucinous neoplasm with main duct involvement: an international expert survey and case-vignette study. *Surgery* 2018;164(1):17–23.
6. Truty MJ, Kendrick ML, Nagorney DM, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. *Ann Surg*. Epub 5 Apr 2019. <https://doi.org/10.1097/sla.0000000000003284>.
7. Stoop TF, Ateeb Z, Ghorbani P, et al. Surgical outcomes after total pancreatectomy: a high-volume center experience. *Ann Surg Oncol*. 2020. <https://doi.org/10.1245/s10434-020-08957-x>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.